New drug could free diabetics from insulin after cell transplant
NCT ID NCT06305286
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study tests whether a lab-made antibody called Tegoprubart can safely prevent the immune system from attacking transplanted islet cells in people with type 1 diabetes who have dangerous low blood sugar. The goal is to help patients stop needing insulin without using standard anti-rejection drugs that can harm the new cells. Up to 70 adults aged 18-65 will receive the antibody and be monitored for insulin independence and blood sugar control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- FitBit coaching may help amputees walk more after surgery
- Can AI catch the leading cause of blindness before It's too late?
- Does feeling stigmatized worsen life quality for men with low testosterone?
- Can community hospitals in zambia master severe disease care?
- Can a wearable sensor beat Finger-Prick tests for type 2 diabetes?
- Brain training may sharpen aging minds in diabetes